Joseph R. Taylor

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

13h-index1.8kcitations32works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hormonal Regulation and Hypertension(5), Diabetes Treatment and Management(4), Pancreatic function and diabetes(4), Pharmacogenetics and Drug Metabolism(2), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(2)

Publications32 total

College Enrollment and Retention in Texas
Student Affairs on Campus·2025· 1 citedOpen Access
Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disorders
Bioorganic & Medicinal Chemistry Letters·2025
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132)
Journal of Medicinal Chemistry·2022· 9 citedOpen Access
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA<sub>1</sub>) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
Journal of Medicinal Chemistry·2021· 53 citedOpen Access
Curriculum mapping as a tool to identify changes in regulator learning outcomes for undergraduate dental programmes in the UK
2021
LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation
2019· 11 cited
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)
ACS Medicinal Chemistry Letters·2018· 5 citedOpen Access
Discovery of Clinical Candidate 2-((2<i>S</i>,6<i>S</i>)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor
Journal of Medicinal Chemistry·2017· 14 citedOpen Access
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)
ACS Medicinal Chemistry Letters·2014· 22 citedOpen Access
Oral‐Motor Development in Infants
Encyclopedia of Special Education·2014
Graphic Organizers
Encyclopedia of Special Education·2014
11β-Hydroxysteroid Dehydrogenase Type 1 Gene Knockout Attenuates Atherosclerosis and In Vivo Foam Cell Formation in Hyperlipidemic apoE−/− Mice
PLoS ONE·2013· 31 citedOpen Access
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)
Bioorganic & Medicinal Chemistry Letters·2011· 27 citedOpen Access
Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity
Journal of Medicinal Chemistry·2009· 70 citedOpen Access
Oral‐Motor Development in Infants
Encyclopedia of Special Education·2008
Graphic Organizers
Encyclopedia of Special Education·2008
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Diabetes·2008· 416 citedOpen Access
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Journal of Medicinal Chemistry·2008· 613 citedOpen Access
Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses
International Journal of Dermatology·2001· 239 citedOpen Access
Novel Benzofuran and Benzothiophene Biphenyls as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties
Journal of Medicinal Chemistry·2000· 210 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jeffrey A. Robl(7), Rachel Zebo(6), Nathan Morgan(5), Jean M. Whaley(5), Rajasree Golla(5), Ramakrishna Seethala(5), Jun Li(5), Thomas Harrity(5), Wei Meng(4), Bruce A. Ellsworth(4), Shiwei Tao(4), Lawrence J. Kennedy(4), Steven J. Walker(4), Yan Shi(4), Stephen Kalinowski(4), Bradley A. Zinker(4), David A. Gordon(4), Shung Wu(4), David Yoon(4), Randolph Ponticiello(4)